CCA
EBS icon

Childress Capital Advisors’s Emergent Biosolutions EBS Stock Holding History

Childress Capital Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-253
Closed -$23K – 397
2020
Q4 		$23K Buy
+253
New +$23.2K 0.01% 330

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Childress Capital Advisors's EBS Position: Q1 2021 in Review

Childress Capital Advisors sold out of Emergent Biosolutions (EBS) in Q1 2021, closing a stake of 253 shares — an estimated $23K sold.

Childress Capital Advisors first reported a position in EBS in Q4 2020 and held it in 1 quarter. The position peaked at $23K in Q4 2020. 340 funds tracked by Wall St. Rank hold EBS as of Q1 2021.

  • Childress Capital Advisors reported no remaining Emergent Biosolutions position as of Q1 2021 after selling out during the quarter.
  • Childress Capital Advisors sold 253 Emergent Biosolutions shares in Q1 2021, an estimated $23K.
  • Childress Capital Advisors first reported a position in Emergent Biosolutions in Q4 2020 and held it in 1 quarter.
  • Childress Capital Advisors's Emergent Biosolutions position peaked at $23K in Q4 2020.
  • 340 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2021.

Based on Childress Capital Advisors's 13F filing for Q1 2021, filed 21 May 2021.